The First Regioselective Metalation and Functionalization of Unprotected 4-Halobenzoic Acids
摘要:
By treatment with s-BuLi, s-BuLi/TMEDA, or t-BuLi at similar to-78 degreesC, 4-fluoro- and 4-chlorobenzoic acids (1a,b) are metalated preferentially in the position adjacent to the carboxylate. A complete reversal in regioselectivity is observed for 1a when treated with LTMP; a sequential process involving a rapid intraaggregate lithiation through a quasi dianion complex "QUADAC" is postulated to explain the unusual reactivity of Me2S2 and I-2.
TRI-FUNCTIONAL UV-ABSORBING COMPOUNDS AND USE THEREOF
申请人:Domschke Angelika Maria
公开号:US20100168359A1
公开(公告)日:2010-07-01
Described herein are tri-functional compounds useful in the production of ophthalmic lenses. The compounds are composed of UV absorber having a polymerization initiator directly or indirectly bonded to the ultraviolet absorber, and an olefinic group directly or indirectly bonded to the ultraviolet absorber. Also described herein are polymers and ophthalmic lenses produced from the tri-functional compounds described herein.
The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.
18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
申请人:DEUTSCHES KREBSFORSCHUNGSZENTRUM
公开号:US10016519B2
公开(公告)日:2018-07-10
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
本发明一般涉及放射性药物领域及其在核医学中作为示踪剂、成像剂和治疗前列腺癌各种疾病状态的用途。
18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
申请人:DEUTSCHES KREBSFORSCHUNGSZENTRUM
公开号:US20170246327A1
公开(公告)日:2017-08-31
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
申请人:InventisBio LLC
公开号:US20220054486A1
公开(公告)日:2022-02-24
The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.